$ServiceNow(NOW)$ NVDA CEO Jensen Huang's point is that powerful AI goes beyond just having a big language model. To build useful AI systems, you need software that ties the model into an organization's data, tools, and workflows. That means connecting AI to enterprise data sources like databases, documents, CRMs, and ERPs, giving it access to software tools and APIs so it can actually take actions instead of just answering questions, handling memory, security, permissions, and governance, orchestrating multiple models and agents to work together, and monitoring, evaluating, and updating the systems in production.
$SpaceX(SPCX)$ I managed to make $204 on the bounce. Still holding a small position for the launch. A pop and drop would be pretty nice, so I could cash in and then rebuy.
$Micron Technology(MU)$ $SK hynix(SKHY)$ The KOSPI is making a slow climb, though it's still below recent highs. Forced selling from margin calls seems to be one factor holding back a faster rebound. This pressure is partly coming from leveraged ETFs, which have been falling several times more than their underlying investments. Meanwhile, major investment banks like Morgan Stanley and JPMorgan have been calling to buy semiconductors, saying the sell-off was overdone. However, any buying that has appeared has been quickly sold into. It feels like a lot of retail investors lost money after institutions crashed the party, and it might be wise to not rush back in. Institutions may need to provide more
$IBM(IBM)$ Earnings are out soon. I think shorts might look to cover, possibly pushing the price toward $215. They'll likely want to lock in profits. That's just my view.
$Aquestive Therapeutics Inc.(AQST)$ We're into Q3 now, so we should find out soon about the US FDA submission for AQST, along with the PK studies updates and the labeling plan with the agency. The question is whether it's going to be a Class 1 Resubmission or a Regular submission. For $Outlook Therapeutics, Inc.(OTLK)$ , there are only 8 days left until a potential massive US FDA approval decision.
$IBM(IBM)$ Does a $600 million miss really justify a $70 billion drop in market cap? This whole situation feels way overdone. The idea that it's just retail selling off seems off to me.